Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL

Dr Paolo Ghia talks to ecancer about the phase 2 CAPTIVATE study.
It demonstrated that first-line treatment with ibrutinib and venetoclax in CLL/SLL patients provided a 5-year progression-free survival (PFS) rate of 67% and overall survival (OS) rate of 96%.
Higher PFS was seen in patients with undetectable minimal residual disease (MRD).
Patients with high-risk genomic features had varied PFS rates, with 41% for those with del(17p)/mutated TP53.
Retreatment with ibrutinib alone or with venetoclax showed promising response rates (86% and 71%, respectively).
The combination therapy offers durable benefits, especially for high-risk patients.